You are here

Home » Content

Renin Anjiyotensin Sistemi İnhibisyonu Enkapsüle Periton Sklerozu Gelişmesini Engelleyebilir

Renin Angiotensin System Inhibition may Prevent Progression of Encapsulated Peritoneal Sclerosis

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Encapsulated Peritoneal Sclerosis (EPS) is a devastating complication of long-term peritoneal dialysis (PD) patients. Angiotensin-2 is a well-known agent that promotes fibrosis and inflammation in the course of various inflammatory diseases. We aimed to investigate the effects of enalapril (ENA), valsartan (VAL) and ENA plus VAL (COMB) on the progression (P) of EPS induced by chlorhexidine gluconate (CG). Forty-two non-uremic wistar albino rats were divided into five groups: Control group: 2 ml isotonic saline intraperitoneally (IP) daily, CG group: IP 2 ml/200 g injection of CG (0.1%) and ethanol (15%) dissolved in saline; All treatment groups received CG solution plus the following: ENA-P group: 100 mg/L ENA, VAL-P group: 640 mg/L VAL, COMB-P group: 100 mg/L ENA + 640 mg/L VAL, given daily for 3 weeks in drinking water. ENA and VAL have beneficial effects on peritoneal functional and morphological alterations induced by CG via inhibition of neoangiogenesis, increased UF volume and decreased peritoneal thickness and dialysate cell count. Dual blockage of renin angiotensin system (RAS) has no additional benefits except improved peritoneal thickness.
Bookmark/Search this post with
Abstract (Original Language): 
Enkapsüle Periton Sklerozu (EPS), sürekli ayaktan periton diyalizi (PD) hastalarında ortaya çıkabilen ağır bir komplikasyondur. Altta yatan patofizyoloji yeni damar oluşumu, fibrozis ve inflamasyondur. Anjiyotensin II birçok hastalığın seyrinde inflamasyon ve fibrozis gelişimine katkıda bulunur. Bu çalışmanın amacı, renin anjiyotensin sistemi inhibisyonunun EPS progresyonu üzerine etkisini araştırmaktır. Kırk iki üremik olmayan wistar albino sıçan, beş gruba ayrıldı. Kontrol grubu (n:10): Periton içine (İP) 2 ml izotonik, Klorheksidin glukonat (CG) grubu (n:10): İP %0,1 CG ve %15 etanol verildi. Tüm tedavi grubu sıçanlara CG solüsyonu ile birlikte Enalapril-Progresyon grubunda (ENA-P) (n:8): 100 mg/L enalapril, Valsartan-Progresyon grubunda (VAL-P) (n=7): 640 mg/L valsartan ve Kombinasyon-Progresyon grubunda (KOMB-P) (n=7): 100 mg/L enalapril + 640 mg/L valsartan 3 hafta boyunca her gün içme sularına katılarak verildi. Enalapril ve Valsartan; yeni damar oluşumunu engellemek, UF volümünü arttırmak, periton kalınlığını ve diyalizat hücre sayısını azaltmak suretiyle, CG’ nin neden olduğu morfolojik değişiklikler ve bozulmuş periton fonksiyonları üzerine olumlu etkiler göstermiştir. RAS’ın ikili inhibisyonu periton kalınlığı hariç ek fayda sağlamamıştır. Sonuç olarak, EPS progresyonunu önlemede, RAS blokajı; membran bütünlüğünü korumak suretiyle yeni bir tedavi seçeneği olabilir.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_18_pp_112-116.pdf
  • 3
112-116
  • Turkish

REFERENCES

References: 

1. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M,
Newman GR, Mackenzie RK, Williams GT: Morphologic
changes in the peritoneal membrane of patients with renal
disease. J Am Soc Nephrol 2002; 13:470–479
2. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB:
Angiotensin II mediates high glucose-induced TGF-beta1
and fibronectin upregulation in HPMC through reactive
oxygen species. Perit Dial Int 2005; 25:38–47
3. Zweers MM, Struijk DG, Smit W, Krediet RT: Vascular
endothelial growth factor in peritoneal dialysis: A
longitudinal follow-up. J Lab Clin Med 2001; 137:125–32
HÜR E ve ark: Renin Anjiyotensin Sistemi İnhibisyonu
Enkapsüle Periton Sklerozu Gelişmesini Engelleyebilir
Cilt/Vol. 18, No, 3, 2009 Sayfa/Page 112-116
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
4. Ha H, Cha MK, Choi HN, Lee HB: Effects of peritoneal
dialysis solutions on the secretion of growth factors
and extracellular matrix proteins by human peritoneal
mesothelial cells. Perit Dial Int 2002; 22:171–177
5. Lee HB, Yu MR, Song JS, Ha H: Reactive oxygen species
amplify protein kinase C signaling in high glucose-induced
fibronectin expression by peritoneal mesothelial cells.
Kidney Int 2004; 65: 170–179
6. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin-
II stimulates extracellular matrix protein synthesis through
induction of transforming growth factor ß expression in rat
glomerular mesangial cells. J Clin Invest 1994; 93: 2431–
2437
7. Duman S, Wieczorowska-Tobis K, Styszynski A,
Kwiatkowska B, Breborowicz A, Oreopoulos DG:
Intraperitoneal enalapril ameliorates morphologic changes
induced by hypertonic peritoneal dialysis solutions in rat
peritoneum. Adv Perit Dial. 2004;20:31-36
8. Duman S, Sen S, Duman C, Oreopoulos DG: Effect of
valsartan versus lisinopril on peritoneal sclerosis in rats. Int
J Artif Organs. 2005;28(2):156-163
9. Duman S, Breborowicz A: The renin-angiotensin system
and peritoneal dialysis. Perit Dial Int 2004;24(1): 5-9
10. Bozkurt D, Cetin P, Sipahi S, Hur H, Nar H, Ertilav M,
Sezak M, Duman S: The effects of renin–angiotensin
system inhibition on regression of encapsulating peritoneal
sclerosis. Perit Dial Int 2008; 28(5):38–42
11. Honda K, Oda H: Pathology of encapsulating peritoneal
sclerosis. Perit Dial Int 2005; 25(Suppl 4):19–29
12. Mateijsen MA, van der Wal AC, Hendriks PM, Zweers
MM, Mulder J, Struijk DG, Krediet RT: Vascular and
interstitial changes in the peritoneum of CAPD patients
with peritoneal sclerosis. Perit Dial Int 1999; 19:517–525
13. Kawanishi H: Encapsulating peritoneal sclerosis.
Nephrology (Carlton) 2005; 10:249–255
14. Kyuden Y, Ito T, Masaki T, Yorioka N, Kohno N: TGFbeta1induced
by high glucose is controlled by angiotensinconverting
enzyme inhibitor and angiotensin II receptor
blocker on cultured human peritoneal mesothelial cells.
Perit Dial Int 2005; 25:483–491
15. Selgas R, Bajo A, Jiménez-Heffernan JA, Sánchez-Tomero
JA, Del Peso G, Auilera A: Epithelial-to-mesenchymal
transition of the mesothelial cell its role in the response of
the peritoneum to dialysis. Nephrol Dial Transplant 2006;
21 (Suppl 2):ii,2–7
16. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido
J: Proinflammatory actions of angiotensins. Curr Opin
Nephrol Hypertens 2001; 10:321–329
17. Wolf G, Neilson EG: Angiotensin II as a renal growth factor.
J Am Soc Nephrol 1993; 3:1531–1540
18. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and
renal fibrosis. Hypertension 2001; 38:635–638
19. Duman S, Günal AI, Sen S, Asçi G, Ozkahya M, Terzioglu
E, Akçiçek F, Atabay G: Does enalapril prevent peritoneal
fibrosis induced by hypertonic (3.86%) peritoneal dialysis
solution? Perit Dial Int 2001; 21:219–224
20. Singh R, Alavi N, Singh AK, Leehey DJ: Role of
angiotensin II in glucose-induced inhibition of mesangial
matrix degradation. Diabetes 1999; 48:2066–2073
21. Hyunjin Noh, Hunjoo Ha, Mi Ra Yu, Young Ok Kim, Ji
Hye Kim, Hi Bahl Lee: Angıotensin II mediates high
glucose-induced Tgf-ß1 and fibronectin upregulation In
Hpmc through reactıve oxygen specıes peritoneal dialysis
international, 2005;25:38–47
22. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effects
of angiotensin converting enzyme inhibition on diabetic
nepropathy. N Engl J Med 1993; 329: 1456–1462
23. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch
WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z,
Shahinfar S: Effects of losartan on renal and cardiovascular
outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med 2001; 345: 861–869
24. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa
I: Cause of variable therapeutic efficiency of angiotensin
converting enzyme inhibitor on glomerular lesions. Kidney
Int 1991; 40:195–202
25. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA,
Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: On behalf of
the Collaborative Study Group. Renoprotective effect of the
angiotensin-receptor antagonist irbesartan in patients with
nephropathy due to type 2 diabetes. N Engl J Med 2001;
345:851–60.
26. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC: Effects
of an angiotensinconverting enzyme inhibitor on residual
renal function in patients receiving peritoneal dialysis. Ann
Intern Med 2003; 139: 105–112
27. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H:
Effects of an Angiotensin II receptor blocker, valsartan, on
residual renal function in patients on CAPD. Am J Kid Dis
2004; 43: 1056–1064
28. Kolesnyk I, Dekker F, Boeschoten E, Krediet R: Angiotensin
II inhibitors and residual GFR in pediatric patients. ERAEDTA
2009

Thank you for copying data from http://www.arastirmax.com